骨肉瘤患者外周血Tc17细胞的比例及其临床意义

Prevalence of Tc17 Cells in the Peripheral Blood of Patients with Osteosarcoma and its Clinical Significance

【目的】分析Tc17细胞在骨肉瘤患者外周血中的分布及其临床意义。【方法】检测41例骨肉瘤患者及17例健康人外周血中Tc17细胞的比例及血浆中白细胞介素-17（IL-17）浓度,分析Tc17细胞比例与IL-17浓度及肿瘤临床分期的关系。【结果】与正常对照组（0.72±0.46）% 相比,骨肉瘤患者外周血中Tc17细胞比例（3.18±1.99）%明显增加,两者相比较差异有显著性（P＜0.01）; 骨肉瘤患者外周血血浆中IL-17浓度显著高于健康对照组; Tc17细胞水平与IL-17浓度、骨肉瘤肿瘤临床分期无明显相关性（P＞0.05）。【结论】骨肉瘤患者外周血Tc17细胞水平明显升高,可能与骨肉瘤患者肿瘤免疫功能低下及肿瘤发生发展密切相关。

【Objective】To investigate the prevalence of Tc17 cells in the peripheral blood of patients with osteosarcoma. 【Methods】Flow cytometry was used to evaluate the prevalence of Tc17 cells in the peripheral blood of 41 patients with osteosarcoma and 17 healthy people. In addition, the concentration of IL-17 was measured. The relationship between peripheral blood Tc17 cell level with the concentration of IL-17 and tumor stage was determined statistically.【Results】The prevalence of Tc17 cells in the peripheral blood of patients with osteosarcoma （3.18±1.99%） increased greatly with increased levels of IL-17, compared with the normal control subjects （0.72±0.46%）. The differences were statistically significant （P〈0.01）. The percentage of Tc17 cells was not associated with the concentration of IL-17 or the stages of osteosarcoma. 【Conclusion】The prevalence of Tc17 cells is increased in the peripheral blood of patients with osteosarcoma.These cells may negatively regulate antitumor immune response of patients.